Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides
Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides
Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides
Selected highlights from the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Amsterdam, The Netherlands
26-28 October 2022
62 slides with notes
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada Read More
Includes a comparison of anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab), depth and duration of B cell suppression, time to B cell reconstitution, and current data on reduced-dose regimens, extended-interval dosing and personalized dosing.
14 slides
Selected highlights from ECTRIMS 2021
Virtual Congress – 13-15 October 2021
52 slides
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada
Read More